LeMaitre Vascular (LMAT)
(Delayed Data from NSDQ)
$82.10 USD
-1.66 (-1.98%)
Updated Aug 12, 2024 04:00 PM ET
After-Market: $81.93 -0.17 (-0.21%) 7:58 PM ET
1-Strong Buy of 5 1
D Value C Growth B Momentum C VGM
Price, Consensus and EPS Surprise
LMAT 82.10 -1.66(-1.98%)
Will LMAT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LMAT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LMAT
LeMaitre (LMAT) Upgraded to Strong Buy: Here's Why
Best Momentum Stock to Buy for August 6th
LMAT: What are Zacks experts saying now?
Zacks Private Portfolio Services
LeMaitre Vascular (LMAT) Surpasses Q2 Earnings and Revenue Estimates
HLN vs. LMAT: Which Stock Is the Better Value Option?
HLN vs. LMAT: Which Stock Should Value Investors Buy Now?
Other News for LMAT
Dividend Champion, Contender, And Challenger Highlights: Week Of August 11
LeMaitre price target raised by $18 at Stifel, here's why
Buy Rating Affirmed for Lemaitre Vascular Amid Strong Fiscal Performance and Growth Prospects
LeMaitre price target raised by $13 at Barrington, here's why
Lemaitre Vascular: A Strong Buy on Sustained Growth and Strategic Acquisitions